Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. 1999

F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
Dept. of Surgical and Gastroenterologic Sciences, University of Padua, School of Medicine, Italy. cc1@ux1.unipd.it

The aim of this study was to evaluate CEA and CA 15-3 changes in patients surgically treated for breast cancer. One hundred and three women (median age 59 years, range 31-83 years) with pT1-2, pN0-1, M0 breast cancer were followed up for at least 5 years. CEA and CA 15-3 serum levels were measured before operation and every 6 months during follow-up. The diagnostic sensitivity of CEA and CA 15-3 was 22.3% and 33.3% respectively. There was a significant difference (p < 0.01) between pre- and post-operative (6 months and 5 years after surgery) mean CEA serum levels independent of TNM staging. During follow-up, 21 (20.4%) patients showed recurrence of cancer and overall CEA and CA 15-3 sensitivity was 38.1% and 61.1%, with 98.8% and 91.2% specificity, respectively. Tumor marker measurement may be useful in post-surgical follow-up, but at present they are neither sensitive nor specific enough for early diagnosis of malignancy.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
January 2000, Anticancer research,
F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
January 1989, Archives of gynecology and obstetrics,
F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
May 1992, Helvetica chirurgica acta,
F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
January 1991, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
January 2001, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
October 2008, International journal of clinical oncology,
F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
January 1997, Anticancer research,
F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
January 1999, Anticancer research,
F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
January 1993, Cancer detection and prevention,
F Lumachi, and A A Brandes, and P Boccagni, and F Polistina, and G Favia, and D F D'Amico
March 2004, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!